Standout Papers
Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells
2017
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
2018
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
2020
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
2017 Standout
Breast cancer
2019 Standout
Immunotherapy and targeted therapy combinations in metastatic breast cancer
2019
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
2009
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
Breast cancer statistics, 2019
2019 Standout
The Placebo Effect: Dissolving the Expectancy Versus Conditioning Debate.
2004 Standout
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
2014
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Cellular senescence in aging and age-related disease: from mechanisms to therapy
2015 Standout
Disgust as a disease-avoidance mechanism.
2009 Standout
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
2008 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Hepatocellular carcinoma
2021 Standout
Ticlopidine
1990
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Recent Advances in the Treatment of Breast Cancer
2018
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
CDK4/6 inhibition triggers anti-tumour immunity
2017 Nature
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
Classical conditioning and the placebo effect
1997
Tripping on nothing: placebo psychedelics and contextual factors
2020 Standout
The Neuroendocrinology of Stress: A Never Ending Story
2008 Standout
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
2013
Enhanced onset of platelet inhibition with a loading dose of ticlopidine in ASA-treated stable coronary patients
1998 StandoutNobel
Cognitive Stimulation in Patients with Dementia: Randomized Controlled Trial
2013 Standout
Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology
2006
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Cognitive stimulation to improve cognitive functioning in people with dementia
2012
Breast Cancer Statistics, 2022
2022 Standout
The placebo effect as a conditioned response: Failures of the “litmus test”
1991
Advances and controversies in the management of soft tissue sarcomas
2016
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
2016
Breast Cancer Treatment
2019 Standout
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
2020
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought
2007 Standout
American Trip
2020 Standout
Works of Eric Gauthier being referenced
Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)
2012
Sorafenib in patients with progressive epithelioid hemangioendothelioma
2013
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
2019
Méthode de prise en charge globale non médicamenteuse des patients déments institutionnalisés
2005
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Time course of long-term placebo therapy effects in angina pectoris
1986
Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT).
2012
Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors
2009
Failure of a Pure Anti-Platelet Drug to Decrease the Number of Attacks More Than Placebo in Patients With Raynaud's Phenomenon
1986
A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.
2013
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).
2016
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
2018